ErBb Family Proteins in Cholangiocarcinoma and Clinical Implications

Journal of Clinical Medicine

Wook Jin¹ 

[1] Laboratory of Molecular Disease and Cell Regulation, Department of Biochemistry, School of Medicine, Gachon University, Incheon 406-840, Korea;

关键词: Epidermal growth factor receptor (EGFR) family;    cholangiocarcinoma;    aggressiveness;    mutation;    chemoresistance;    EGFR family-targeting inhibitors;   

DOI  :  10.3390/jcm9072255

来源: DOAJ

【 摘 要 】

The erythroblastic leukemia viral oncogene homolog (ErBb) family consists of the receptor tyrosine kinases (RTK) epidermal growth factor receptor (EGFR; also called ERBB1), ERBB2, ERBB3, and ERBB4. This family is closely associated with the progression of cholangiocarcinoma (CC) through the regulation of cellular networks, which are enhanced during tumorigenesis, metastasis, and chemoresistance. Additionally, the constitutive activation of cellular signaling by the overexpression and somatic mutation-mediated alterations conferred by the ErBb family on cholangiocarcinoma and other cancers enhances tumor aggressiveness and chemoresistance by contributing to the tumor microenvironment. This review summarizes the recent findings on the molecular functions of the ErBb family and their mutations during the progression of cholangiocarcinoma. It also discusses the developments and applications of various devising strategies for targeting the ErBb family through different inhibitors in various stages of clinical trials, which are essential for improving targeted clinical therapies.

【 授权许可】

Unknown